New to Bioss? Enjoy 35% of your first order. Use code "FirstOrder35" - Offer valid for new U.S. Customers on direct orders only

PIM1(Tyr309) Polyclonal Antibody, AbBy Fluor® 350 Conjugated

Applications

  • WB
  • IF(IHC-P)
  • IF(IHC-F)
  • IF(ICC)

Reactivity

  • Human
  • Mouse
  • Rat

Predicted Reactivity

  • Dog
  • Cow
  • Sheep
  • Pig
  • Rabbit
Overview
Catalog # bs-3353R-BF350
Product Name PIM1(Tyr309) Polyclonal Antibody, AbBy Fluor® 350 Conjugated
Applications WB, IF(IHC-P), IF(IHC-F), IF(ICC)
Specificity This phosphorylation site is also referred to as Tyr218, as this is the position in Isoform 2 of this protein. This phosphorylation site is homologous to Tyr302 in Mouse and Tyr218 in Rat.
Reactivity Human, Mouse, Rat
Predicted Reactivity Dog, Cow, Sheep, Pig, Rabbit
Specifications
Conjugation AbBy Fluor® 350
Host Rabbit
Source KLH conjugated synthetic phosphopeptide derived from human PIM1 around the phosphorylation site of Tyr218
Modification Site Tyr309
Clonality Polyclonal
Isotype IgG
Concentration 1ug/ul
Purification Purified by Protein A.
Storage Buffer Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Storage Condition Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Target
Gene ID 5292
Swiss Prot P11309
Subcellular location Cytoplasm, Nucleus, Cell membrane
Synonyms PIM; Serine/threonine-protein kinase pim-1; PIM1
Background Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation and thus providing a selective advantage in tumorigenesis. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression and by phosphorylation and inhibition of proapoptotic proteins (BAD, MAP3K5, FOXO3). Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase of transcriptional activity. The stabilization of MYC exerted by PIM1 might explain partly the strong synergism between these two oncogenes in tumorigenesis. Mediates survival signaling through phosphorylation of BAD, which induces release of the anti-apoptotic protein Bcl-X(L)/BCL2L1. Phosphorylation of MAP3K5, an other proapoptotic protein, by PIM1, significantly decreases MAP3K5 kinase activity and inhibits MAP3K5-mediated phosphorylation of JNK and JNK/p38MAPK subsequently reducing caspase-3 activation and cell apoptosis. Stimulates cell cycle progression at the G1-S and G2-M transitions by phosphorylation of CDC25A and CDC25C. Phosphorylation of CDKN1A, a regulator of cell cycle progression at G1, results in the relocation of CDKN1A to the cytoplasm and enhanced CDKN1A protein stability. Promote cell cycle progression and tumorigenesis by down-regulating expression of a regulator of cell cycle progression, CDKN1B, at both transcriptional and post-translational levels. Phosphorylation of CDKN1B,induces 14-3-3-proteins binding, nuclear export and proteasome-dependent degradation. May affect the structure or silencing of chromatin by phosphorylating HP1 gamma/CBX3. Acts also as a regulator of homing and migration of bone marrow cells involving functional interaction with the CXCL12-CXCR4 signaling axis.
Application Dilution
WB 1:300-5000
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200